Please ensure Javascript is enabled for purposes of website accessibility

Want to Make Money in Biotech? Do This First

By Brian Orelli, PhD and Keith Speights - May 7, 2021 at 5:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Keeping track of upcoming events is important.

Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (HRTX 8.83%), for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, Alkermes (ALKS 2.67%) expects an FDA decision on its schizophrenia and bipolar treatment ALKS3831 on or before June 1.

In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the best ways to keep abreast of news that biotech companies release. They discuss websites that aggregate that information, but investors with a small number of biotechs in their portfolios might be best off just keeping abreast of what those companies are up to through their websites and SEC disclosures.

Brian Orelli: RA asks: "What is the best way to research biotech stocks to find important dates or trial news?"

Keith Speights: That's a great question. There's a website that I use. Brian, if you have an answer while I'm looking for this website. [laughs]

Orelli: Yeah, go ahead and find the website. Honestly, mostly what I do is I read the company press releases, and that has all the information that you need. Occasionally you have to find it in an SEC document, but usually, the companies are pretty open about putting it in their press releases, or, at the very least, saying it on their conference calls. So look for the transcripts of the conference calls.

There are plenty of websites that Keith is going to bring up that aggregate this information, but they're all getting that information just from the individual press releases. If you've just got a couple of biotechs, the easiest way is just to look at the press releases.

Speights: RA, I will share a link to the website that I use myself. It's an FDA calendar that biopharmcatalyst.com has. It's pretty good. It has the upcoming FDA decisions and PDUFA dates and clinical study readouts, that kind of thing. I've found that it's useful, so I'll share that.

Brian Orelli, PhD and Keith Speights have no position in any of the stocks mentioned. The Motley Fool recommends Alkermes. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
ALKS
$26.15 (2.67%) $0.68
Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$5.30 (8.83%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.